NCT02947386View on ClinicalTrials.gov

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 29, 2017

Primary Completion Date

April 15, 2021

Study Completion Date

September 8, 2022

Conditions
EGFR Gene MutationRecurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nimotuzumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT02947386 - Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter